Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

A multi-site feasibility study to assess fever and wheezing in children after influenza vaccines using text messaging.

Stockwell MS, Marchant CD, Wodi AP, Barnett ED, Broder KR, Jakob K, Lewis P, Kattan M, Rezendes AM, Barrett A, Sharma D, Fernandez N, LaRussa P.

Vaccine. 2017 Dec 15;35(50):6941-6948. doi: 10.1016/j.vaccine.2017.10.073. Epub 2017 Oct 28.

2.

Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children.

Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI.

Pediatr Infect Dis J. 2014 May;33(5):504-10. doi: 10.1097/INF.0000000000000279.

PMID:
24670957
3.

Comprehensive assessment of serious adverse events following immunization by health care providers.

Williams SE, Edwards KM, Baxter RP, LaRussa PS, Halsey NA, Dekker CL, Vellozzi C, Marchant CD, Donofrio PD, Reimschisel TE, Berger M, Gidudu JF, Klein NP.

J Pediatr. 2013 Jun;162(6):1276-81, 1281.e1. doi: 10.1016/j.jpeds.2013.01.028. Epub 2013 Feb 26. No abstract available.

PMID:
23452584
4.

Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination.

Pahud BA, Williams SE, Dekker CL, Halsey N, Larussa P, Baxter RP, Klein NP, Marchant CD, Sparks RC, Jakob K, Aukes L, Swope S, Barnett E, Lewis P, Berger M, Dreskin SC, Donofrio PD, Sejvar JJ, Slade BA, Gidudu J, Vellozzi C, Edwards KM.

Pediatr Infect Dis J. 2013 Feb;32(2):163-8. doi: 10.1097/INF.0b013e318271b90a.

PMID:
23334340
5.

Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).

Loughlin AM, Marchant CD, Adams W, Barnett E, Baxter R, Black S, Casey C, Dekker C, Edwards KM, Klein J, Klein NP, LaRussa P, Sparks R, Jakob K.

Vaccine. 2012 Nov 26;30(50):7253-9. doi: 10.1016/j.vaccine.2012.09.074. Epub 2012 Oct 9.

PMID:
23063829
6.

Biologically plausible and evidence-based risk intervals in immunization safety research.

Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, Vellozzi C, Fireman B, Sejvar JJ, Halsey NA, Baxter R; Risk Interval Working Group of the Clinical Immunization Safety Assessment Network.

Vaccine. 2012 Dec 17;31(1):271-7. doi: 10.1016/j.vaccine.2012.07.024. Epub 2012 Jul 24. Review.

PMID:
22835735
7.

Prevalence and genetic diversity of nontypeable haemophilus influenzae in the respiratory tract of infants and primary caregivers.

Schumacher SK, Marchant CD, Loughlin AM, Bouchet V, Stevenson A, Pelton SI.

Pediatr Infect Dis J. 2012 Feb;31(2):145-9. doi: 10.1097/INF.0b013e31823aaeb3.

8.

Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.

Williams SE, Pahud BA, Vellozzi C, Donofrio PD, Dekker CL, Halsey N, Klein NP, Baxter RP, Marchant CD, Larussa PS, Barnett ED, Tokars JI, McGeeney BE, Sparks RC, Aukes LL, Jakob K, Coronel S, Sejvar JJ, Slade BA, Edwards KM.

Vaccine. 2011 Oct 26;29(46):8302-8. doi: 10.1016/j.vaccine.2011.08.093. Epub 2011 Sep 3.

9.

Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.

Williams SE, Klein NP, Halsey N, Dekker CL, Baxter RP, Marchant CD, LaRussa PS, Sparks RC, Tokars JI, Pahud BA, Aukes L, Jakob K, Coronel S, Choi H, Slade BA, Edwards KM.

Vaccine. 2011 Sep 16;29(40):6920-7. doi: 10.1016/j.vaccine.2011.07.044. Epub 2011 Jul 27. Review.

10.

Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants.

Bryant KA, Marshall GS, Marchant CD, Pavia-Ruiz N, Nolan T, Rinderknecht S, Blatter M, Aris E, Lestrate P, Boutriau D, Friedland LR, Miller JM.

Pediatrics. 2011 Jun;127(6):e1375-85. doi: 10.1542/peds.2009-2992. Epub 2011 May 29.

PMID:
21624883
12.

Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.

Marshall GS, Marchant CD, Blatter M, Aris E, Boutriau D, Poolman JT, Friedland LR, Miller JM.

Pediatr Infect Dis J. 2010 May;29(5):469-71. doi: 10.1097/INF.0b013e3181cdd379.

PMID:
20072077
13.

Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.

Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, Boutriau D; HibMenCY-TT 005 Study Group.

Pediatr Infect Dis J. 2010 Jan;29(1):48-52. doi: 10.1097/INF.0b013e3181c3ce88.

PMID:
20035207
14.

Immunogenicity and safety of an inactivated hepatitis a vaccine administered concomitantly with a pneumococcal conjugate vaccine in healthy children 15 months of age.

Trofa AF, Levin M, Marchant CD, Hedrick J, Blatter MM.

Pediatr Infect Dis J. 2008 Jul;27(7):658-60. doi: 10.1097/INF.0b013e31816907bd.

PMID:
18536623
15.

Universal hepatitis A vaccination in the United States: a call for action.

Lieberman JM, Word BM, Jacobs RJ, Dagan R, Marchant CD.

Pediatr Infect Dis J. 2008 Apr;27(4):287-91. doi: 10.1097/INF.0b013e31815efe4b.

PMID:
18316993
16.

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS; Protocol 016 Study Group.

Pediatrics. 2006 Nov;118(5):2135-45.

PMID:
17079588
17.

Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad).

Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, Shinefield H, Reisinger KS, Marchant CD, Sullivan BJ, Thear M, Klopfer S, Xu J, Gress JO, Schödel F; Study Group for ProQuad.

Hum Vaccin. 2006 Sep-Oct;2(5):205-14.

PMID:
17035730
18.

The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.

Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ; Consistency Lot Study Group for ProQuad.

Pediatr Infect Dis J. 2006 Jul;25(7):615-22.

PMID:
16804432
19.

Effectiveness of Centers for Disease Control and Prevention recommendations for outcomes of acute otitis media.

Bauchner H, Marchant CD, Bisbee A, Heeren T, Wang B, McCabe M, Pelton S; Boston-Based Pediatric Research Group.

Pediatrics. 2006 Apr;117(4):1009-17.

PMID:
16585294
20.

Fluoroquinolone use in children.

Sabharwal V, Marchant CD.

Pediatr Infect Dis J. 2006 Mar;25(3):257-8. Review. No abstract available.

PMID:
16511391
21.

Gatifloxacin therapy for children: an antibiotic still in the "back room".

Marchant CD.

Clin Infect Dis. 2005 Aug 15;41(4):479-80. Epub 2005 Jul 13. No abstract available.

PMID:
16028154
22.

Pertussis: increasing incidence and the need for booster vaccination in adolescents. Introduction.

Marchant CD.

Pediatr Infect Dis J. 2005 Jun;24(6 Suppl):S103. No abstract available.

PMID:
15931136
23.

The 100-day cough: the time for prevention has arrived.

Marchant CD.

Clin Infect Dis. 2004 Dec 1;39(11):1581-2. Epub 2004 Nov 10. No abstract available.

PMID:
15578354
25.

Acute otitis media, antibiotics, children and clinical trial design.

Marchant CD.

Pediatr Infect Dis J. 2002 Oct;21(10):891-3. No abstract available.

PMID:
12394808
26.

Treatment of acute otitis media consensus recommendations.

Hoberman A, Marchant CD, Kaplan SL, Feldman S.

Clin Pediatr (Phila). 2002 Jul-Aug;41(6):373-90. Review.

PMID:
12166789
27.

Antimicrobial guidelines for the treatment of acute bacterial rhinosinusitis in immunocompetent children.

Poole MD, Jacobs MR, Anon JB, Marchant CD, Hoberman A, Harrison CJ.

Int J Pediatr Otorhinolaryngol. 2002 Mar 15;63(1):1-13. Review.

PMID:
11879923
28.

A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993.

Christie CD, Garrison KM, Kiely L, Gupta RK, Heubi J, Marchant CD.

Clin Infect Dis. 2001 Oct 1;33(7):997-1003. Epub 2001 Sep 5.

PMID:
11528571
29.

Otitis media: a preventable disease? Proceedings of an international symposium organized by the Marcel Mérieux Foundation, Veyrier-du-Lac, France, February 13 to 16, 2000.

Klein JO, Chonmaitree T, Loosmore S, Marchant CD, Ruuskanen O, Shinefield HR.

Pediatr Infect Dis J. 2001 May;20(5):473-81. Review. No abstract available.

PMID:
11368103
30.

The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998.

Yih WK, Lett SM, des Vignes FN, Garrison KM, Sipe PL, Marchant CD.

J Infect Dis. 2000 Nov;182(5):1409-16. Epub 2000 Oct 9.

PMID:
11023464
31.

Pneumococcal conjugate vaccines.

Marchant CD.

Pediatr Ann. 1999 Aug;28(8):540-5. No abstract available.

PMID:
10483599
32.
33.

The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children.

Christie CD, Marx ML, Marchant CD, Reising SF.

N Engl J Med. 1994 Jul 7;331(1):16-21.

34.

Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness.

Marchant CD, Loughlin AM, Lett SM, Todd CW, Wetterlow LH, Bicchieri R, Higham S, Etkind P, Silva E, Siber GR.

J Infect Dis. 1994 Jun;169(6):1297-305.

PMID:
8195607
35.

Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children.

Shurin PA, Rehmus JM, Johnson CE, Marchant CD, Carlin SA, Super DM, Van Hare GF, Jones PK, Ambrosino DM, Siber GR.

J Pediatr. 1993 Nov;123(5):801-10.

PMID:
8229496
36.

Efficacy of Haemophilus influenzae type b vaccines in Massachusetts children 18 to 59 months of age.

Loughlin AM, Marchant CD, Lett S, Shapiro ED.

Pediatr Infect Dis J. 1992 May;11(5):374-9.

PMID:
1630857
37.

Measuring the comparative efficacy of antibacterial agents for acute otitis media: the "Pollyanna phenomenon".

Marchant CD, Carlin SA, Johnson CE, Shurin PA.

J Pediatr. 1992 Jan;120(1):72-7.

PMID:
1731027
38.

Volume of varicella-zoster immune globulin.

Marchant CD, Leszczynski J.

Pediatr Infect Dis J. 1991 Jun;10(6):476. No abstract available.

PMID:
1649433
39.

Host factors and early therapeutic response in acute otitis media.

Carlin SA, Marchant CD, Shurin PA, Johnson CE, Super DM, Rehmus JM.

J Pediatr. 1991 Feb;118(2):178-83.

PMID:
1899699
40.

Acute phase reactants and risk of bacterial meningitis among febrile infants and children.

Lembo RM, Marchant CD.

Ann Emerg Med. 1991 Jan;20(1):36-40.

PMID:
1984725
41.
42.
43.

The Red Ear-drum: To Treat or Not To Treat?

Marchant CD.

Can Fam Physician. 1989 Sep;35:1841-4.

44.

Depression of anticapsular antibody after immunization with Haemophilus influenzae type b polysaccharide-diphtheria conjugate vaccine.

Marchant CD, Band E, Froeschle JE, McVerry PH.

Pediatr Infect Dis J. 1989 Aug;8(8):508-11.

PMID:
2788860
45.

Recent advances in otitis media. Diagnosis and screening.

Gates GA, Northern JL, Ferrer HP, Jerger J, Marchant CD, Fiellau-Nikolajsen M, Ranney JB, Renvall U, Ruben RJ, Stewart I, et al.

Ann Otol Rhinol Laryngol Suppl. 1989 Apr;139:39-41. Review. No abstract available.

PMID:
2494929
46.

Recent advances in otitis media. Epidemiology and natural history.

Teele DW, Lundgren K, Casselbrant ML, Daly KA, Ingvarsson L, Karma P, Marchant CD, Roydhouse N, Tos M, van Cauwenberge PB, et al.

Ann Otol Rhinol Laryngol Suppl. 1989 Apr;139:11-3. No abstract available.

PMID:
2494924
47.

Serous and recurrent otitis media. Pharmacological or surgical management?

Marchant CD, Collison LM.

Drugs. 1987 Dec;34(6):695-701. Review.

PMID:
3322783
48.

Quantitative measurement of C-reactive protein in acute otitis media.

Komoroski EM, Van Hare G, Shurin PA, Vahey J, Johnson C, Marchant CD, Scillian J.

J Pediatr. 1987 Jul;111(1):81-4. No abstract available.

PMID:
3496442
49.

Early recurrences of otitis media: reinfection or relapse?

Carlin SA, Marchant CD, Shurin PA, Johnson CE, Murdell-Panek D, Barenkamp SJ.

J Pediatr. 1987 Jan;110(1):20-5. Erratum in: J Pediatr 1987 Apr;110(4):668.

PMID:
3540247
50.

Acute otitis media caused by Branhamella catarrhalis: biology and therapy.

Van Hare GF, Shurin PA, Marchant CD, Cartelli NA, Johnson CE, Fulton D, Carlin S, Kim CH.

Rev Infect Dis. 1987 Jan-Feb;9(1):16-27.

PMID:
3493519

Supplemental Content

Loading ...
Support Center